magnesium supplement (OTC)

Magnesium Deficiency

168-336 mg PO divided BID

Renal Insufficiency

CrCl<30 mL/min: Use caution; monitor for hypermagnesemia

CrCl≥30 mL/min: Dose adjustement not necessary

Safety & efficacy not established

Contraindicated (2)

• baloxavir marboxil

  magnesium supplement will decrease the level or effect of baloxavir marboxil by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

• raltegravir

  magnesium supplement will decrease the level or effect of raltegravir by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

Serious - Use Alternative (0)

Monitor Closely (50)

• alendronate

  magnesium supplement will decrease the level or effect of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• amikacin

  magnesium supplement, amikacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• amlodipine

  magnesium supplement, amlodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• atracurium

  magnesium supplement, atracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• bictegravir

  magnesium supplement will decrease the level or effect of bictegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

• calcitriol

  magnesium supplement will increase the level or effect of calcitriol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

• ciprofloxacin

  magnesium supplement will decrease the level or effect of ciprofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

• cisatracurium

  magnesium supplement, cisatracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• clevidipine

  magnesium supplement, clevidipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• deferiprone

  magnesium supplement will decrease the level or effect of deferiprone by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 4 hr from polyvalent cation administration

• delafloxacin

  magnesium supplement will decrease the level or effect of delafloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

• demeclocycline

  magnesium supplement will decrease the level or effect of demeclocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• diltiazem

  magnesium supplement, diltiazem. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• dolutegravir

  magnesium supplement will decrease the level or effect of dolutegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

• doxercalciferol

  magnesium supplement will increase the level or effect of doxercalciferol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

• doxycycline

  magnesium supplement will decrease the level or effect of doxycycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• eltrombopag

  magnesium supplement will decrease the level or effect of eltrombopag by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 4 hr after

• etidronate

  magnesium supplement will decrease the level or effect of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• felodipine

  magnesium supplement, felodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• gabapentin

  magnesium supplement will decrease the level or effect of gabapentin by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 2 hr from polyvalent cation administration

• gemifloxacin

  magnesium supplement will decrease the level or effect of gemifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 3hr after the quinolone

• gentamicin

  magnesium supplement, gentamicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• ibandronate

  magnesium supplement will decrease the level or effect of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• isradipine

  magnesium supplement, isradipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• levofloxacin

  magnesium supplement will decrease the level or effect of levofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 2hr after the quinolone

• levothyroxine

  magnesium supplement will decrease the level or effect of levothyroxine by Other (see comment). Modify Therapy/Monitor Closely. Drug may adsorb to magnesium; may decrease absorption by the intestinal tract; applies to oral forms; may separate administration of drugs by 4 hr

• minocycline

  magnesium supplement will decrease the level or effect of minocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• moxifloxacin

  magnesium supplement will decrease the level or effect of moxifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 4hr before the quinolone or 8hr after the quinolone

• mycophenolate

  magnesium supplement will decrease the level or effect of mycophenolate by Other (see comment). Modify Therapy/Monitor Closely. Drug may bind to magnesium ions in the GI tract, which decreases absorption; separate administration of drugs to minimize interaction

• neomycin PO

  magnesium supplement, neomycin PO. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• nicardipine

  magnesium supplement, nicardipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nifedipine

  magnesium supplement, nifedipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nimodipine

  magnesium supplement, nimodipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nisoldipine

  magnesium supplement, nisoldipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• omadacycline

  magnesium supplement will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..
  
  magnesium supplement will decrease the level or effect of omadacycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• pancuronium

  magnesium supplement, pancuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• penicillamine

  magnesium supplement will decrease the level or effect of penicillamine by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 1 hr from polyvalent cation administration

• plazomicin

  magnesium supplement, plazomicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• potassium phosphate

  magnesium supplement will decrease the level or effect of potassium phosphate by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with divalent cations; may decrease absorption by the intestinal tract; applies to oral forms; separate administration of drugs to avoid interaction

• risedronate

  magnesium supplement will decrease the level or effect of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• rocuronium

  magnesium supplement, rocuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• sarecycline

  magnesium supplement will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..
  
  magnesium supplement will decrease the level or effect of sarecycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• streptomycin

  magnesium supplement, streptomycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• succinylcholine

  magnesium supplement, succinylcholine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• tetracycline

  magnesium supplement will decrease the level or effect of tetracycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline

• tiludronate

  magnesium supplement will decrease the level or effect of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• tobramycin

  magnesium supplement, tobramycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• trientine

  magnesium supplement will decrease the level or effect of trientine by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 1hr before the trietine or 1hr after the trientine

• vecuronium

  magnesium supplement, vecuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• verapamil

  magnesium supplement, verapamil. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

Minor (0)

• alendronate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• amikacin

  Monitor Closely (1)magnesium supplement, amikacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• amlodipine

  Monitor Closely (1)magnesium supplement, amlodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• atracurium

  Monitor Closely (1)magnesium supplement, atracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• baloxavir marboxil

  Contraindicated (1)magnesium supplement will decrease the level or effect of baloxavir marboxil by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

• bictegravir

  Monitor Closely (1)magnesium supplement will decrease the level or effect of bictegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

• calcitriol

  Monitor Closely (1)magnesium supplement will increase the level or effect of calcitriol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

• ciprofloxacin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of ciprofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

• cisatracurium

  Monitor Closely (1)magnesium supplement, cisatracurium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• clevidipine

  Monitor Closely (1)magnesium supplement, clevidipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• deferiprone

  Monitor Closely (1)magnesium supplement will decrease the level or effect of deferiprone by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 4 hr from polyvalent cation administration

• delafloxacin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of delafloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone

• demeclocycline

  Monitor Closely (1)magnesium supplement will decrease the level or effect of demeclocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• diltiazem

  Monitor Closely (1)magnesium supplement, diltiazem. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• dolutegravir

  Monitor Closely (1)magnesium supplement will decrease the level or effect of dolutegravir by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after

• doxercalciferol

  Monitor Closely (1)magnesium supplement will increase the level or effect of doxercalciferol by Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia

• doxycycline

  Monitor Closely (1)magnesium supplement will decrease the level or effect of doxycycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• eltrombopag

  Monitor Closely (1)magnesium supplement will decrease the level or effect of eltrombopag by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 4 hr after

• etidronate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• felodipine

  Monitor Closely (1)magnesium supplement, felodipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• gabapentin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of gabapentin by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 2 hr from polyvalent cation administration

• gemifloxacin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of gemifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 3hr after the quinolone

• gentamicin

  Monitor Closely (1)magnesium supplement, gentamicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• ibandronate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• isradipine

  Monitor Closely (1)magnesium supplement, isradipine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• levofloxacin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of levofloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 2hr after the quinolone

• levothyroxine

  Monitor Closely (1)magnesium supplement will decrease the level or effect of levothyroxine by Other (see comment). Modify Therapy/Monitor Closely. Drug may adsorb to magnesium; may decrease absorption by the intestinal tract; applies to oral forms; may separate administration of drugs by 4 hr

• minocycline

  Monitor Closely (1)magnesium supplement will decrease the level or effect of minocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• moxifloxacin

  Monitor Closely (1)magnesium supplement will decrease the level or effect of moxifloxacin by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 4hr before the quinolone or 8hr after the quinolone

• mycophenolate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of mycophenolate by Other (see comment). Modify Therapy/Monitor Closely. Drug may bind to magnesium ions in the GI tract, which decreases absorption; separate administration of drugs to minimize interaction

• neomycin PO

  Monitor Closely (1)magnesium supplement, neomycin PO. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• nicardipine

  Monitor Closely (1)magnesium supplement, nicardipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nifedipine

  Monitor Closely (1)magnesium supplement, nifedipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nimodipine

  Monitor Closely (1)magnesium supplement, nimodipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• nisoldipine

  Monitor Closely (1)magnesium supplement, nisoldipine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.

• omadacycline

  Monitor Closely (2)magnesium supplement will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..
  
  magnesium supplement will decrease the level or effect of omadacycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• pancuronium

  Monitor Closely (1)magnesium supplement, pancuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• penicillamine

  Monitor Closely (1)magnesium supplement will decrease the level or effect of penicillamine by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 1 hr from polyvalent cation administration

• plazomicin

  Monitor Closely (1)magnesium supplement, plazomicin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• potassium phosphate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of potassium phosphate by Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with divalent cations; may decrease absorption by the intestinal tract; applies to oral forms; separate administration of drugs to avoid interaction

• raltegravir

  Contraindicated (1)magnesium supplement will decrease the level or effect of raltegravir by Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms

• risedronate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• rocuronium

  Monitor Closely (1)magnesium supplement, rocuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• sarecycline

  Monitor Closely (2)magnesium supplement will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline..
  
  magnesium supplement will decrease the level or effect of sarecycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• streptomycin

  Monitor Closely (1)magnesium supplement, streptomycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• succinylcholine

  Monitor Closely (1)magnesium supplement, succinylcholine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• tetracycline

  Monitor Closely (1)magnesium supplement will decrease the level or effect of tetracycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline

• tiludronate

  Monitor Closely (1)magnesium supplement will decrease the level or effect of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative

• tobramycin

  Monitor Closely (1)magnesium supplement, tobramycin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• trientine

  Monitor Closely (1)magnesium supplement will decrease the level or effect of trientine by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 1hr before the trietine or 1hr after the trientine

• vecuronium

  Monitor Closely (1)magnesium supplement, vecuronium. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects.

• verapamil

  Monitor Closely (1)magnesium supplement, verapamil. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers.